INT182749

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2005
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.55
Pain Relevance 0.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Hmgcr) embryo development (Hmgcr)
Anatomy Link Frequency
external 1
Hmgcr (Mus musculus)
Pain Link Frequency Relevance Heat
Spinal cord 16 99.88 Very High Very High Very High
imagery 21 95.56 Very High Very High Very High
medulla 2 53.60 Quite High
nud 1 39.60 Quite Low
ketamine 1 30.28 Quite Low
interstitial cystitis 8 5.00 Very Low Very Low Very Low
Inflammation 4 5.00 Very Low Very Low Very Low
unmyelinated 2 5.00 Very Low Very Low Very Low
cytokine 1 5.00 Very Low Very Low Very Low
Peripheral nervous system 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Mevalonate Kinase Deficiency 58 97.42 Very High Very High Very High
Death 2 72.68 Quite High
Dislocations 2 72.24 Quite High
Syndrome 3 43.84 Quite Low
Dyspepsia 1 39.60 Quite Low
Fever 5 29.04 Quite Low
Interstitial Cystitis 9 5.00 Very Low Very Low Very Low
INFLAMMATION 4 5.00 Very Low Very Low Very Low
Targeted Disruption 3 5.00 Very Low Very Low Very Low
Disease 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Compatibility of NV Jade with NV Red and NV Maroon for Long-Distance 3-Color Neurotracing
NV Red Binding (Compatibility) of
1) Confidence 0.32 Published 2007 Journal Immunological Investigations Section Body Doc Link PMC2430174 Disease Relevance 0 Pain Relevance 0.22
Sections were also stained with hematoxylin and eosin (H&E) and a low-pH Alcian Blue counterstained with Nuclear Fast Red.
Red Binding (counterstained) of
2) Confidence 0.05 Published 2005 Journal BMC Urol Section Body Doc Link PMC1079893 Disease Relevance 0.14 Pain Relevance 0
Previously, we showed in vitro that treatment of MKD cells with simvastatin may lead to an increase of residual MK activity, whereas at the same time, the consequence of inhibiting HMG-CoA reductase appears to be negative for flux through the isoprenoid biosynthesis pathway (Schneiders et al 2006).These findings indicated that one needs to be cautious when treating MKD patients with simvastatin, because the balance between inhibiting HMG-CoA reductase and inducing MK activity may be critical, especially in MKD patients in whom the pathway flux is very sensitive to external influences.
HMG-CoA reductase Neg (negative) Binding (negative) of in external associated with mevalonate kinase deficiency
3) Confidence 0.05 Published 2010 Journal J Inherit Metab Dis Section Body Doc Link PMC2946549 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox